Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...
The growth in the heart closure devices market from 2024-2030 is mainly driven by several factors: the rising incidence of congenital heart defects, increased use of MRI procedures, greater awareness ...
MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
Atrial fibrillation treatment with device closure matched anticoagulants and reduced bleeding risk. Discover what this means for AF care.
(MENAFN- EIN Presswire) EINPresswire/ -- The global biopsy closure device market is entering a high-growth phase, projected to expand from USD 574.6 million in 2026 to USD 1,323.3 million by 2036, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results